ACADIA Pharmaceuticals Inc. Common Stock (ACAD)

About ACAD

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

796

Website

acadia.com/

Fundamentals

1-day range

$30.07$30.96

Market cap

$4.87B

P/E (trailing)

12.85

P/E (forward)

34.20

EPS (trailing)

$2.21

Dividend yield

—

Beta

0.86

Avg. volume

1.62M

Forecasts

20 analyst ratings

ACADIA Pharmaceuticals Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• ACAD

  ACADIA Pharmaceuticals Inc. Common Stock

  $29.13

  ▼ 2.02%
  Market cap $4.87BP/E 12.85
  $19.69$30.96
• INDV

  Indivior Pharmaceuticals Inc. Common Stock

  $34.87

  ▼ 1.22%
  Market cap $4.82BP/E 12.77
  $22.22$42.81
• MANE

  Veradermics Incorporated Common Stock

  $97.53

  ▼ 4.20%
  Market cap $4.54BP/E —
  $32$131.24
• GRFS

  Grifols S.A. American Depositary Shares

  $7.68

  ▼ 1.79%
  Market cap $5.38BP/E 13.31
  $8.43$12.87
• MIRM

  Mirum Pharmaceuticals Inc. Common Stock

  $97.44

  ▼ 2.32%
  Market cap $5.74BP/E —
  $63.23$130
• VKTX

  Viking Therapeutics Inc. Common Stock

  $32.15

  ▼ 5.05%
  Market cap $3.88BP/E —
  $22.96$43.15
• PTCT

  PTC Therapeutics Inc. Common Stock

  $70.01

  ▼ 2.51%
  Market cap $5.91BP/E —
  $48.86$90.87

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Deutsche Bank Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $38
  benzinga · 8/25/2026
• Deutsche Bank Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $38
  Benzinga · 8/25/2026
• Morgan Stanley Maintains Equal-Weight on ACADIA Pharmaceuticals, Raises Price Target to $28
  Benzinga · 8/25/2026
• Citigroup Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $40
  Benzinga · 8/25/2026
• Acadia Pharmaceuticals: Another Bite At The Alzheimer's Apple
  SeekingAlpha · 8/24/2026
• UBS Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $49
  Benzinga · 8/17/2026
• Needham Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $41
  Benzinga · 8/12/2026
• Citigroup Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $39
  Benzinga · 8/10/2026
• Stoke: 'Buy' On Zorevunersen NDA SCN1A DS And STK-002 Advancement
  SeekingAlpha · 8/5/2026

• Schneyer Mark C. · August 6, 2026 · Option Exercise

  14.3K @ $17.84
• Schneyer Mark C. · August 6, 2026 · Sale

  9.3K @ $29.34
• Schneyer Mark C. · August 6, 2026 · Sale

  5.0K @ $29
• Schneyer Mark C. · August 5, 2026 · Option Exercise

  5.8K @ $17.84
• Schneyer Mark C. · August 5, 2026 · Sale

  5.8K @ $29
• Thompson Elizabeth H.Z. · July 30, 2026 · Sale

  50 @ $26.17
• Thompson Elizabeth H.Z. · July 30, 2026 · Sale

  16.5K @ $26.13
• Thompson Elizabeth H.Z. · July 29, 2026 · Option Exercise

  32.3K
• BAKER BROS. ADVISORS LP · May 29, 2026 · Grant

  32.0K
• BAKER BROS. ADVISORS LP · May 29, 2026 · Grant

  18.6K
• Adora Ndu · May 29, 2026 · Grant

  9.3K
• Adora Ndu · May 29, 2026 · Grant

  16.0K
• Adora Ndu · May 29, 2026 · Option Exercise

  8.1K
• Elizabeth A. Garofalo · May 29, 2026 · Grant

  9.3K
• Elizabeth A. Garofalo · May 29, 2026 · Grant

  16.0K

Institutional Ownership

March 31, 2026

Total shares held

155.65M

Total value held

$3.42B

Institutional holders

336